accuRx raises £27.5m in Series B funding led by Lakestar to expand healthcare communication tools.
The Series B round was led by Lakestar with backing from institutional investors and venture funds to support team growth and product expansion.
Share allotment filed at Companies House
AccuRx builds software designed to assist doctors in reducing inappropriate antibiotic prescriptions.
Healthcare communication platform accuRx has secured £27.5m in a Series B funding round led by Lakestar. Participation in the round came from British Patient Capital, Latitude Ventures, Atomico, Trusted Insight and Encore Capital.
The fresh capital will be directed towards expanding the company team and scaling its product offerings. accuRx plans to enhance its existing tools for general practices while building new infrastructure to support expansion into secondary care settings.
The London-based company has experienced rapid adoption across the National Health Service, with its software currently utilised by the vast majority of English GP practices. During the pandemic, the platform supported frontline staff with remote consultations and a vaccine booking system used for millions of COVID-19 inoculations.
From the founder
"accuRx’s product has reinvigorated communication with our patients, enabling a better relationship between GPs and patients, which has ultimately led to better care provision. Our patients now have the confidence that they’re getting speedy and accurate responses from our team, and the use of regular Florey questionnaires to gather more information from our patients has been transformative for clinical record keeping and the care we provide. We’re thrilled that accuRx has received funding which will enable it to expand its primary care product set, some of which we’re trialling at the moment. We’re also excited about accuRx’s progress into secondary care as better interaction between primary and secondary care is a huge step forward for safer and more effective patient care."
David Triska
GP Partner at AccuRx
Investor perspective
"An overhaul of communications in the healthcare industry is long overdue. Inefficient communication between nurses, doctors, general practitioners, to name a few, is tremendously detrimental to patients. We see this issue in healthcare sectors around the world and the pandemic has only heightened the need for action. We’re proud of what accuRx has been able to accomplish so far in transforming communication within primary care and we can’t wait to see the great benefits its tools will afford secondary care as well. With its product suite, accuRx has the potential to become a crucial backbone and infrastructure of healthcare markets globally,"
Oliver Heimes
Partner, Lakestar
Use of funds
- 01Grow the team
- 02Continue product development
- 03Expand into international markets
Investors
Categories
About the company
AccuRx
AccuRx develops clinical software to combat anti-microbial resistance.